Orkambi

Orkambi (Lumacaftor; Ivacaftor) is a combination therapy developed to address the underlying cause of cystic fibrosis in individuals with specific genetic variations of the CFTR gene. It is designed for people who have two copies of the F508del mutation, one of the most common genetic changes associated with this condition. By targeting the defective CFTR protein, Orkambi helps improve its function at the cellular level.
Lumacaftor works by assisting the CFTR protein in forming the correct shape and moving to the cell surface, where it is needed to regulate the movement of salt and water. Ivacaftor enhances the activity of the CFTR protein once it reaches the cell surface, allowing chloride ions to pass through more effectively. Together, these actions help restore better balance of salt and water in the lungs and other organs.
Improved CFTR function supports thinner mucus in the airways, which can make breathing easier and reduce the buildup that contributes to lung infections. Consistent use has been associated with better lung performance, fewer respiratory complications, and improved overall daily functioning for eligible individuals. The therapy also supports better nutritional absorption by improving CFTR activity in the digestive system.
Orkambi is taken orally and is intended for long-term use as part of a comprehensive cystic fibrosis care plan. Regular monitoring is important to assess liver function, breathing status, and overall response during ongoing use. Some individuals may experience effects such as chest tightness, changes in breathing patterns, or digestive discomfort, especially during the initial phase.
By addressing the root protein defect rather than only symptoms, Orkambi represents a targeted approach that has changed the management landscape for cystic fibrosis linked to the F508del mutation.